Loop F D
The Cleveland Clinic Foundation, OH 44195, USA.
Eur J Cardiothorac Surg. 1998 Dec;14(6):554-71. doi: 10.1016/s1010-7940(98)00249-8.
In each of the first three decades of myocardial revascularization, conventional treatment has been revised completely. This lecture comments on three areas of discovery that have shaped the evolution of myocardial revascularization: science, technology development, and revascularization. The discoveries in all three areas are inexorably interrelated. The single greatest lesson learned so far is that conduit performance carries more prognostic weight than any other factor. We have observed that vein graft atherosclerosis is predictable, and that the first-generation lipid lowering drugs have a favorable effect in patients who achieve marked LDL reduction. Biologically better revascularization begins with use of the internal thoracic artery for grafting to the anterior descending coronary artery. As the results of internal thoracic artery grafting are widely reported, arterial bypass revascularization has expanded, notably by radial and gastroepiploic arteries. The results of bilateral internal thoracic artery grafting are discussed, including large-scale registry results of internal thoracic artery usage in the United States. The internal thoracic artery is significantly underutilized. Diabetes affects both endoluminal and surgical revascularization. The new pharmacology in cardiology interventions shows promise in diminishing restenosis and thrombosis even in diabetic patients. Conversely, extended internal thoracic artery grafting may also benefit diabetic patients. Now we are entering a new age of minimally invasive coronary surgery. We have passed through the early stages of mini-thoracotomy, and we are moving on to access through 1-cm ports, intrathoracic cannulation, antegrade and retrograde myocardial protection, and computer guided three-dimensional vision and instrumentation. The potential for robotic control adds greater precision, ease of use, and safety. This new technology will be integrated with diagnostic information, intraoperative monitoring, anesthesia and perfusion data, cost accounting, and surgical note transcription. The operating room of the future will package intraoperative information and is adaptable to all surgical specialties. The future of coronary artery surgery will depend on minimally invasive techniques, all-arterial grafting, and selective lipid modification to reduce progressive atherosclerosis. The conclusion of this decade marks the end of the beginning. The new generation of cardiothoracic surgeons will share in an array of technology and research unmatched in previous decades.
在心肌血运重建的头三个十年里,传统治疗方法都得到了彻底修订。本次讲座将对塑造心肌血运重建发展的三个发现领域进行评论:科学、技术发展和血运重建。这三个领域的发现有着千丝万缕的联系。到目前为止,我们学到的最深刻的教训是,血管桥性能比任何其他因素都更具预后权重。我们观察到静脉桥粥样硬化是可预测的,并且第一代降脂药物对低密度脂蛋白显著降低的患者有良好效果。生物学上更好的血运重建始于使用胸廓内动脉移植至冠状动脉前降支。随着胸廓内动脉移植结果的广泛报道,动脉搭桥血运重建得到了扩展,特别是通过桡动脉和胃网膜动脉。讨论了双侧胸廓内动脉移植的结果,包括美国胸廓内动脉使用的大规模注册研究结果。胸廓内动脉的使用明显不足。糖尿病会影响腔内和外科血运重建。心脏病介入治疗中的新药在减少再狭窄和血栓形成方面显示出前景,即使是糖尿病患者也是如此。相反,扩大胸廓内动脉移植也可能使糖尿病患者受益。现在我们正进入微创冠状动脉手术的新时代。我们已经走过了小切口开胸手术的早期阶段,正在迈向通过1厘米端口进入、胸腔内插管、顺行和逆行心肌保护以及计算机引导的三维视觉和器械操作。机器人控制的潜力增加了更高的精度、易用性和安全性。这项新技术将与诊断信息、术中监测、麻醉和灌注数据、成本核算以及手术记录转录相结合。未来的手术室将整合术中信息,并适用于所有外科专业。冠状动脉手术的未来将取决于微创技术、全动脉移植以及选择性脂质修饰以减少进行性动脉粥样硬化。这十年的结束标志着开始的结束。新一代心胸外科医生将拥有一系列前几十年无与伦比的技术和研究成果。